Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MORECreative Biolabs offers the world leading custom TCR development service with the most advanced techniques and years of experiences to establish the solid platform for TCR production. Our technical experts are looking forward to designing a strategy of TCR biomarker identification & selection required for your assays and will be able to recommend an approach appropriate to your project needs.
Adoptive transfer of T cells gene-engineered with antigen-specific T cell receptors (TCRs) has proven its feasibility and therapeutic potential in the treatment of tumors. To ensure clinical development of TCR gene therapy, it is necessary to target immunogenic epitopes that result in optimal T cell fitness. Ideally, target antigens are selectively expressed by tumor tissue but not healthy tissue, and hence not expected to evoke a response against self. At the same time, target antigens should have proficient immunogenicity to initiate an effective anti-tumor response.
As the most basic foundation of therapeutic effect, these TCR biomarkers commonly possess the following principles:
Creative Biolabs provides our clients almost all the discovered cancer targets or other disease and novel ones in the evaluation for TCR therapy. Like CEA for colorectal, HER2 for breast cancer, BEV for Hodgkin lymphomas, STEAP1forEwing’s sarcoma, TOSO for rhabdomyosarcoma, SSX2 for synovial sarcomas, BMLF-1 for Epstein-Barr virus, gp41 for HIV, IE for cytomegalovirus, NS3 for hepatitis C virus, HBc18-27 for hepatitis B virus, VSV8 for vesicular stomatitis Indiana virus, etc. More than that, our experts have the best knowledge reserves and a wealth of research experience and the ability to discover new targets for our customers.
Fig.1 The Featured Target Marker of TCRs
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by sending E-mail and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
